Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
6 studies found for:    alzheimer's genentech
Show Display Options
RSS Create an RSS feed from your search for:
alzheimer's genentech
Need help? See RSS Feeds
Choose a feed type:
Show studies that were first received in the last 14 daysShow studies that were first received in the last 14 days
Show studies added or modified in the last 14 daysShow studies that were added or modified in the last 14 days
Rank Status Study
1 Completed A Study to Evaluate the Efficacy and Safety of MABT5102A in Patients With Mild to Moderate Alzheimer's Disease (ABBY)
Condition: Alzheimer's Disease
Interventions: Drug: MABT5102A;   Drug: placebo
2 Recruiting A Study of Crenezumab Versus Placebo in Preclinical PSEN1 E280A Mutation Carriers to Evaluate Efficacy and Safety in the Treatment of Autosomal-Dominant Alzheimer Disease, Including a Placebo-Treated Noncarrier Cohort.
Condition: Alzheimer Disease
Interventions: Drug: crenezumab;   Drug: placebo
3 Completed A Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Anti-Abeta (MABT5102A) in Patients With Alzheimer's Disease
Condition: Alzheimer's Disease
Interventions: Drug: anti-Abeta;   Drug: placebo
4 Completed A Study to Evaluate the Impact of MABT5102A on Brain Amyloid Load and Related Biomarkers in Patients With Mild to Moderate Alzheimer's Disease
Condition: Alzheimer's Disease
Interventions: Drug: MABT5102A;   Drug: placebo
5 Active, not recruiting A Long-Term Safety Extension Study of Studies ABE4869g And ABE4955g in Patients With Mild To Moderate Alzheimer's Disease Treated With Crenezumab
Condition: Alzheimer Disease
Intervention: Drug: crenezumab
6 Recruiting A Study of Crenezumab in Patients With Mild to Moderate Alzheimer Disease (AD)
Condition: Alzheimer Disease
Interventions: Drug: crenezumab dose level 1;   Drug: crenezumab dose level 2;   Drug: placebo dose level 1;   Drug: placebo dose level 2

Indicates status has not been verified in more than two years